3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
2
Unknown
1
Terminated
1
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Breast
1
Conditions
Breast Neoplasms
36
Neoplasms
7
Neoplasm Metastasis
7
Endometrial Neoplasms
7
Ovarian Neoplasms
5
Triple Negative Breast Neoplasms
4
Breast Diseases
3
Brain Neoplasms
3
Sarcoma
2
Neoplasms by Site
2
Meningioma
2
Liposarcoma
2
Glioblastoma
2
Fallopian Tube Neoplasms
2
Breast Neoplasms, Male
2
Uterine Cervical Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Sarcoma, Kaposi
1
Retinoblastoma
1
Recurrent Ovarian High Grade Serous Adenocarcinoma
1
Recurrence
1
Prostatic Neoplasms
1
Pathologic Complete Response
1
Osteosarcoma
1
Neurofibromatosis 1
1
Neoplasm, Residual
1
Multiple Myeloma
1
Medulloblastoma
1
Lymphoma, Non-Hodgkin
1
Lung Neoplasms
1
Interventions
pembrolizumab
25
Cisplatin
17
Carboplatin
13
Radiotherapy
12
Cetuximab
9
Blood Specimen Collection
9
Docetaxel
8
Paclitaxel
7
Fluorouracil
7
Drug Therapy
7
toripalimab
6
tislelizumab
4
nimotuzumab
4
atezolizumab
4
Surveys and Questionnaires
4
Radiation
4
Chemoradiotherapy
4
fludarabine
3
Surgical Procedures, Operative
3
Standard of Care
3
Radiotherapy, Intensity-Modulated
3
Cyclophosphamide
3
Biopsy
3
130-nm albumin-bound paclitaxel
3
cemiplimab
2
avelumab
2
X-Rays
2
Tocopherols
2
Tiragolumab
2
Therapeutics
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Head and Neck Neoplasms
×
abemaciclib
×
Clear all
NCT05768139
2026-06-04
PIKALO-1
Eli Lilly and Company
Phase 1/2
Recruiting
880 enrolled